ClinicalTrials.gg
RecruitingNCT06964087Updated Nov 16, 2026

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

A Phase 2 interventional study of OPT101 and OPT101 Placebo to Match (PTM) in Type I Diabetes, sponsored by Op-T LLC. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Op-T LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 16, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
428th of 1,242
72 · median 40
Started
2026
with 62 others
Phase 2
188 of 1,458
24 open now
Primary completion
2027-05
later than 127 of 258 live
Registered
1,363rd of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 428th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 63 that started in 2026, is one of 188 in phase 2, reaches primary completion later than 127 of the 258 other live ones, and was the 1,363rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.

Read the detailed description

This multipart study begins with an open label exploration of tolerance and pharmacokinetics of subcutaneously (SC) administered OPT101, given at increasing doses of 1.0, 1.5, or 2.0 mg/kg three times per week for two weeks to separate sequential cohorts of six adult patients (n=18 total) diagnosed with type 1 diabetes mellitus within 20 years of screening. In this Part A, serum C-peptide levels will not be a consideration.

In Part B, the highest tolerated dose will then be tested over one year in a total of n=27 subjects having C-peptide 0.2 ng/ml, with 12 diagnosed within 1 to 5 years of screening, and 15 diagnosed within >5 to 10 years. Randomization to treatment or control will be in a 2:1 ratio.

An optional Part C will enroll an additional n=27 subjects having C-peptide 0.2 ng/ml who are 1 year from diagnosis with type 1 diabetes. Subjects will be randomized to treatment or control in a 2:1 ratio and will be treated for one year.

03

Conditions studied

  • Type I Diabetes
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Able and willing and able to give for the trial (separate consent must be obtained for Parts B or C).

    2. Willing to wear a continuous glucose monitor for the duration of the trial (e.g., Freestyle Libre 3).

    3. Male or female aged ≥18 to 50 years on the day of signing informed consent. 4. Diagnosis of T1DM within the last 20 years for Part A, within 1 to 10 years [N=15 at >5 to 10, N=12 at 1 to 5 yrs] for Part B, within less than or equal to 1 year for Part C.

    5. For Parts B and C only, T-cell phenotype Th40 level greater than or equal to 35% of CD3+ leukocytes (performed at the OPT lab).

    6. Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening.

    7. Women of (WOCBP) must have a negative highly sensitive serum test (beta- human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1 Day 1 prior to receiving the product.

    8. WOCBP must agree to use one of the following methods of for the duration of the clinical trial: Systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device.

Exclusion criteria

Exclusion Criteria:

  • 1. Current or history of malignancy other than basal cell carcinoma or squamous cell carcinoma in situ.

    2. Has an immune deficiency syndrome (for example, severe combined immunodeficiency syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic granulomatous disease), or bone marrow or organ transplantation, or a disease associated with lymphopenia.

    3. Has chronic kidney disease of Stage 2 or higher with of \<90 mL/min/1.73m2.

    4. Is currently receiving an immuno-modulatory treatment. 5. Patients with a history of venous and arterial thromboembolic events including, but not limited to, the following:

    1. Deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, , or arterial insufficiency causing digital gangrene.
    2. Patients with recent immobilization or recent surgery.
    3. Patients with a history of abnormal prothrombotic laboratories such as congenital or inherited deficiency of antithrombin III, protein C, protein S, or confirmed diagnosis of antiphospholipid syndrome.

      6. Has an active infections, is prone to infections or has chronic, recurrent or opportunistic infectious disease, including but not limited to, Epstein-Barr virus, cytomegalovirus, chronic renal infection, chronic chest infection, sinusitis, recurrent urinary tract infection, Pneumocystis carinii pneumonia, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis or an open, draining, or infected non-healing skin wound or ulcer.

      7. Has recent or active hepatitis A infection, current/chronic and infection, or infection. Participants with immunity to hepatitis B from previous infection, defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody [anti-HBs] or vaccination [defined as negative HBsAg, negative anti-HBc, and positive anti-HBs] are eligible to participate.

      8. Has a history of latent or active tuberculosis. 9. Has received a within the last 60 days including patients who plan to receive live attenuated vaccines during the study or within 60 days after the final dose of study treatment.

      10. Patients with the following should be excluded:

    <!-- -->

    1. Abnormal coagulation test at screening: (PT; >14 sec), activated partial thromboplastin time (aPTT; >32 sec) or fibrinogen level (\<190 or >450 mg/dL).
    2. Abnormal liver function tests (except in the case of known Gilbert's syndrome):

    i. or ALT ≥3x and total ≥2x ULN ii. AST or ALT ≥5x ULN iii. Abnormal counts (\<150 or > 450 x10 to the third/uL) iv. Abnormal white blood cell counts (\< 3.0 or >11.0 x10 to the third/uL ) v. Abnormal eGFR (\< 90 mL/min) vi. Abnormal Factor VIII (\<50% or >150% of normal) vii. Abnormal D-Dimer (> 500 ng/mL of fibrinogen equivalent units (FEU)) 11. Patients planning to undergo elective procedures or surgeries at any time after signing the ICF through the follow-up visit.

    12. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.

    13. Recent history of bleeding or bleeding disorders or any condition whereby in the opinion of the treating investigator giving anti-coagulation during treatment would be .

    14. History of to antihistamines. 15. \<20 or >35 kg/M2 16. Patients with active drug or alcohol abuse within one year prior to screening or patients who test positive for required drug testing during screening (refer to §8.4).

    17. Patient is participating in a clinical trial of another drug or device, including patients who have participated in another study for duration of 5 half-lives of the investigational agent.

    18. Patient is a prisoner. 19. Patients with any medical condition, including, but not limited to, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or a psychiatric condition that, in the opinion of the Investigator, could compromise their ability to participate in this study.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    OPT101, 1.0mg/kg, 1.5 mg/kg and 2.0 mg/kg

    Part A. 6 subjects will receive 1.0mg/kg OPT101 6 subjects will receive 1.5mg/kg OPT101 6 subjects will receive 2.0mg/kg OPT101

    Drug: OPT101

  • Experimental
    Part B - OPT101 and Placebo to Match

    The highest tolerated dose from Part A will be tested over 48 weeks. 27 subjects (18 investigational product: 9 placebo)

    Drug: OPT101 · Other: OPT101 Placebo to Match (PTM)

  • Experimental
    Part C - OPT101 and Placebo to Match

    The highest tolerated dose in Part A will be dosed. 27 subjects (18 investigational product, 9 placebo)

    Drug: OPT101 · Other: OPT101 Placebo to Match (PTM)

Interventions

  • DrugOPT101

    Subcutaneous injection.

  • OtherOPT101 Placebo to Match (PTM)

    5% Dextrose (w/v)

06

What researchers measure

Primary outcomes

  1. Change in C-peptide (ng/mL)

    Change from baseline to End of Study in mixed-meal stimulated C-peptide (ng/mL). The area under the time-C-Peptide curve (AUC) is calculated, and the weighted mean C-peptide is used to convert the measurement back to nanomoles per liter.

    Time frame: 48-week

Secondary outcomes

  1. PK Parameter - Maximum Concentration (Cmax)

    Maximum Concentration (Cmax)

    Time frame: 48-week

  2. PK Parameter - Time to reach maximum concentration (Tmax)

    Time to reach maximum concentration (Tmax)

    Time frame: 48-week

  3. PK Parameter - terminal half-life t1/2

    Terminal half-life t1/2

    Time frame: 48-week

  4. PK Parameter - Area under the curve

    Area under the curve (AUC)

    Time frame: 48-week

  5. Propotion of subjects with change in C-peptide greater than or equal to 0.2 ng/mL

    Proportion of subjects with mixed-meal stimulated C-peptide peak levels greater than or equal to 0.2 ng/mL at End of Study.

    Time frame: 48-week

07

Study locations

5 of 5 sites recruiting
  • University of Alabama at Birmingham - Department of Medicina
    Birmingham, Alabama 35294, United States
    Recruiting
    • Lisa Boswell · Contactlb@op-t.com · (303) 503-9954
  • Diablo Clinical Research Center
    Walnut Creek, California 94598, United States
    Recruiting
    • Lisa Boswell · Contactlb@op-t.com · (303) 503-9954
  • Barbara Davis Center - University of Colorado Anschuttz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
    • Lisa Boswell · Contactlb@op-t.com · (303) 503-9954
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
    • Lisa Boswell · Contactlb@op-t.com · (303) 503-9954
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
    Recruiting
    • Lisa Boswell · Contactlb@op-t.com · (303) 503-9954
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 13 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → May 2027, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 9, 2025
StartActual
Apr 23, 2026
Primary completionEst.
May 31, 2027was May 2026
CompletionEst.
Aug 19, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 10, 2026→Apr 23, 2026 (actual)
Nov 16, 2026
Primary completion
May 31, 2026→May 31, 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Apr 10, 2026→Apr 23, 2026 (now actual)
    Primary completion May 31, 2026→May 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06964087
Lead sponsor
Op-T LLC
Responsible party
Sponsor
First posted
May 9, 2025
Start date
Apr 23, 2026
Primary completion
May 31, 2027 (estimated)
Completion
Aug 19, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Lisa Boswell
Contact
lb@op-t.com
303-503-9954

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OPT101

Start the discussion